A girl with autosomal dominant hypophosphatemic rickets, presented with clinical, radiological and laboratory signs of rickets at the age of 11 months. She showed a good response to the treatment with low doses of oral phosphate and calcitriol. Surprisingly, she lost her renal phosphate wasting at the age of 8 years, indicating that the disturbed phosphate metabolism can be compensated by hormonal or other factors.

Keywords:
Autosomal dominant hypophosphatemicrickets, X-linked hypophosphatemic rickets, Phosphate-regulating gene, Fibroblast growthfactor 23, Renal phosphate wasting
1.
Winters RW, Graham JB, Williams TF, et al: A genetic study of familial hypophosphatemia and vitamin D-resistant rickets with a review of the literature. Medicine 1958;37:97–142.
2.
Tieder M, Modai D, Samuel R, et al: Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985;312:611–616.
3.
Scriver CR, MacDonald W, Reade T, Glorieux FH, Nogrady B: Hypophosphatemic nonrachitic bone disease: An entity distinct from X-linked hypophosphatemia in the renal defect, bone involvement, and inheritance. Am J Med Genet 1977;1:101–117.
4.
Bianchine JW, Stambler AA, Harrison HE: Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Org Artic Ser 1971;7:287–294.
5.
David L, Pesso JL, Cochat P, Plauchu H, François R: Rachitisme hypophosphatémique autosomique type Scriver: Une observation familiale. Pédiatrie 1987;42:563–568.
6.
Econs MJ, McEnery PT: Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997;82:674–681.
7.
Scriver CR, Reade TM, DeLuca HF, Hamstra AJ: Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978;299:976–979.
8.
HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130–136.
9.
ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345–348.
10.
Kruse K, Hinkel GK, Griefahn B: Calcium metabolism and growth during early treatment of children with X-linked hypophosphatemic rickets. Eur J Pediatr 1998;157:894–900.
11.
Kos CH, Tily F, Econs MJ, Murer H, Lennieux N, Tenenhouse HS: Localization of a renal sodium phosphate cotransporter gene to human chromosome 5q35. Genomics 1994;19:176–177.
12.
Econs MJ, McEnery PT, Lennon F, Speer MC: Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997;100:2653–2657.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.